GlobalData: Anti-Hypertension Therapeutics - Pipeline Assessment And Market Forecasts to 2017

Dec. 7, 2010 - PRLog -- The report identifies the key trends shaping and driving the global hypertension market. The report also provides insight on the competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global hypertension market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

GlobalData estimated the global hypertension market, in 2009, at $36.9 billion indicating a cumulative annual growth rate (CAGR) of 5.3% between 2001 and 2009. The growth in the market can mainly attribute to the growth in the sales of angiotensin renin blockers, the only therapeutic class that has antihypertensive drugs under patent protection. Though ARBs are less effective compared to other drugs such as beta-blockers and calcium channel blockers, they became the frontline treatment for patients diagnosed with hypertension. In addition, the prevalence of hypertension was one of the major factors responsible for the growth of hypertension market between 2001 and 2009. Due to expected patent expiry of blockbusters such as Diovan, Cozaar and Avapro, the market is forecast to decline at a CAGR of -5.2% between 2009 and 2017.

GlobalData analyzed that current competition in the hypertension market is very strong. Drugs acting on the renin angiotensin system dominated the hypertension market in 2009. The patent expiry of key blockbusters and uncertain success of molecule in Phase II and Phase III of development, leads to diminish the hypertension market between 2009 and 2017. The hypertension pipeline is strong. Though there are over 90 molecules in various stages of pipeline for hypertension, majority of them are either me-too products or product extensions of the marketed drugs. More than 34 molecules in the pipeline are me-too drugs and 28 molecules are product extensions of the marketed blockbusters. Big pharmaceutical companies marketing major ARBs are in a race to capture the highest market share in the hypertension market.

The Anti-Hypertension Therapeutics Market is Expected to Witness Steep Decline Due to the Patent Expiry of Blockbusters

GlobalData estimated the global anti-hypertension therapeutics market in 2009 at $36.9 billion, indicating a Compound Annual Growth Rate (CAGR) of 5.3% between 2001 and 2009. The growth in the market can be mainly attributed to the growth in the sales of Angiotensin Renin Blockers (ARB), the only therapeutic class that has anti-hypertensive drugs under patent protection. Though ARBs are less effective compared to other drugs such as beta-blockers (BBs, also known as beta-adrenergic receptor antagonists) and calcium channel blockers (CCBs), they have become the frontline treatment for patients diagnosed with hypertension. The prevalence of hypertension was another major factor responsible for the growth of anti-hypertension therapeutics market between 2001 and 2009. Due to expected patent expiry of blockbusters such as Diovan (valsartan), Cozaar (losartan) and Avapro (irbesartan), the market is forecast to decline at a CAGR of 5.2% between 2009 and 2017 to reach $24 billion in 2017.

The Current Competition in the Anti-Hypertension Therapeutics Market Is Very Strong Since there are Five Therapeutic Classes of Drugs Serving the Market

GlobalData found that the current competition in the anti-hypertension therapeutics market is very strong. The market in 2009 was dominated by ARBs such as Diovan and Avapro. In 2009, agents acting on the renin angiotensin system dominated the anti-hypertension therapeutics market with approximately a 60% share. Among the drugs approved for hypertension, diuretics are the most cost effective drugs. Despite the cost effectiveness and efficacy of diuretics, ARBs and ACE inhibitors are the most widely prescribed anti-hypertensive therapies in the market.

The Anti-Hypertension Therapeutics Market Pipeline is Strong with Good Number of Molecules in Phase II Stage of Pipeline

GlobalData found that there are over 90 molecules in 108 different clinical stages of development in the pipeline. The trail includes combination and monotherapy development. Out of these molecules, 29 are first-in-class, 29 are me-toos, and 17 are generics and the rest are product extensions. Big pharmaceutical companies marketing major ARBs are in a race to capture the highest share in the anti-hypertension therapeutics market. Therefore, these companies are conducting Life Cycle Management (LCM) activities on their blockbuster anti-hypertensive drugs. Some of the LCM activities adopted include expanding into a new patient-base (children less than six years), developing extended release formulations and combining the drugs with other anti-hypertensives. There are only five first-in-class molecules in Phase III of clinical development and the majority of these drugs are not promising. The first-in-class drugs act through new mechanisms of action such as peroxisome proliferator-activated receptors (PPAR) agonism, phosphodiesterase type 5 (PDE5) inhibitor and dual-acting receptor antagonism.

The Current Treatment Options are Very Successful in Regulating Blood Pressure Levels but have Poor Patient Compliance Rates and Moderate Safety Profiles

GlobalData found that the approved treatment options for hypertension are very effective. Hypertension is a chronic disease and therefore patients use the drugs for many years. Patients tend to skip doses due to either forgetfulness or monotony. Skipping doses elevates the Blood Pressure (BP) and leads to hypertension again. Further, skipping doses also has a detrimental effect on the sales of the drugs. Therefore, any drug that can regulate BP for long durations will address the unmet needs.
The other major unmet need is the poor safety profiles. Clinical trial results for the anti-hypertensive drugs indicate that on average, 5% of patients discontinued the study due to adverse effects. Any drug that can minimize the incidence of the side effects will become a promising drug in the anti-hypertension therapeutics market.


GlobalData: Anti-Hypertension Therapeutics - Pipeline Assessment And Market Forecasts to 2017:
http://www.reports-research.com/market-surveys/anti-hyper...

GlobalData: More market data and market reports:
http://www.reports-research.com/market-surveys/globaldata...

# # #

markt-studie.de founded in 2002 has emerged as a leading online portal for market surveys and market research in German speaking areas. Four years later the English language portal reports-research.com was introduced due to the extraordinary success of the portal. Again one year later estudio-mercado.es - the Spanish spoken portal - was founded. The objective of the three portals is to competently and efficiently support consultants and decision makers in management, sales and marketing in the search for worldwide market research. Prospective buyers can look into more than 60,000 market surveys from more than 200 international publishers, current market data for more than 6,000 branches worldwide, 10,000 company profiles as well as a free-of-charge research and recommendation service for individual market research.